Does the media prefer ZYME or RYTM?

In the previous week, Rhythm Pharmaceuticals had 5 more articles in the media than Zymeworks. MarketBeat recorded 7 mentions for Rhythm Pharmaceuticals and 2 mentions for Zymeworks. Zymeworks' average media sentiment score of 0.94 beat Rhythm Pharmaceuticals' score of 0.71 indicating that Zymeworks is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zymeworks 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PTCT or ZYME more profitable?

PTC Therapeutics has a net margin of -22.58% compared to Zymeworks' net margin of -126.92%. Zymeworks' return on equity of -37.97% beat PTC Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets PTC Therapeutics -22.58% -362.45% -6.76% Zymeworks -126.92% -37.97% -25.31%

Does the media favor PTCT or ZYME?

In the previous week, PTC Therapeutics had 17 more articles in the media than Zymeworks. MarketBeat recorded 19 mentions for PTC Therapeutics and 2 mentions for Zymeworks. Zymeworks' average media sentiment score of 0.94 beat PTC Therapeutics' score of 0.48 indicating that Zymeworks is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 9 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zymeworks 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ZYME or MIRM?

In the previous week, Mirum Pharmaceuticals had 2 more articles in the media than Zymeworks. MarketBeat recorded 4 mentions for Mirum Pharmaceuticals and 2 mentions for Zymeworks. Mirum Pharmaceuticals' average media sentiment score of 0.98 beat Zymeworks' score of 0.94 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zymeworks 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CNTA or ZYME?

In the previous week, Centessa Pharmaceuticals had 2 more articles in the media than Zymeworks. MarketBeat recorded 4 mentions for Centessa Pharmaceuticals and 2 mentions for Zymeworks. Zymeworks' average media sentiment score of 0.94 beat Centessa Pharmaceuticals' score of 0.72 indicating that Zymeworks is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Centessa Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zymeworks 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ZYME or RGC?

Zymeworks presently has a consensus price target of $36.67, indicating a potential upside of 51.83%. Given Zymeworks' stronger consensus rating and higher probable upside, equities research analysts clearly believe Zymeworks is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zymeworks 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.82 Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, ZYME or RGC?

Regencell Bioscience has lower revenue, but higher earnings than Zymeworks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zymeworks $105.96M 16.64 -$81.13M -$1.37 N/A Regencell Bioscience N/A N/A -$3.58M N/A N/A

Does the media refer more to ZYME or RGC?

In the previous week, Regencell Bioscience had 13 more articles in the media than Zymeworks. MarketBeat recorded 15 mentions for Regencell Bioscience and 2 mentions for Zymeworks. Zymeworks' average media sentiment score of 0.94 beat Regencell Bioscience's score of 0.08 indicating that Zymeworks is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zymeworks 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regencell Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Zymeworks (ZYME) Competitors

$24.15 +0.38 (+1.60%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$24.42 +0.27 (+1.13%)

As of 06/26/2026 07:59 PM Eastern

Compare

ZYME vs. RYTM, PTCT, MIRM, CNTA, and RGC

Should you buy Zymeworks stock or one of its competitors? MarketBeat compares Zymeworks with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Zymeworks include Rhythm Pharmaceuticals (RYTM), PTC Therapeutics (PTCT), Mirum Pharmaceuticals (MIRM), Centessa Pharmaceuticals (CNTA), and Regencell Bioscience (RGC). These companies are all part of the "pharmaceutical products" industry.

How does Zymeworks compare to Rhythm Pharmaceuticals?

Zymeworks (NASDAQ:ZYME) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

92.9% of Zymeworks shares are owned by institutional investors. 33.5% of Zymeworks shares are owned by insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Zymeworks has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market.

In the previous week, Rhythm Pharmaceuticals had 5 more articles in the media than Zymeworks. MarketBeat recorded 7 mentions for Rhythm Pharmaceuticals and 2 mentions for Zymeworks. Zymeworks' average media sentiment score of 0.94 beat Rhythm Pharmaceuticals' score of 0.71 indicating that Zymeworks is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zymeworks	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zymeworks presently has a consensus price target of $36.67, indicating a potential upside of 51.83%. Rhythm Pharmaceuticals has a consensus price target of $133.13, indicating a potential upside of 21.20%. Given Zymeworks' higher possible upside, research analysts plainly believe Zymeworks is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

Rhythm Pharmaceuticals has a net margin of -93.33% compared to Zymeworks' net margin of -126.92%. Zymeworks' return on equity of -37.97% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-126.92%	-37.97%	-25.31%
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

Zymeworks has higher earnings, but lower revenue than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$105.96M	16.64	-$81.13M	-$1.37	N/A
Rhythm Pharmaceuticals	$189.76M	39.67	-$196.54M	-$3.13	N/A

Summary

Zymeworks beats Rhythm Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Zymeworks compare to PTC Therapeutics?

PTC Therapeutics (NASDAQ:PTCT) and Zymeworks (NASDAQ:ZYME) are both pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends.

PTC Therapeutics has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market. Comparatively, Zymeworks has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market.

PTC Therapeutics has a net margin of -22.58% compared to Zymeworks' net margin of -126.92%. Zymeworks' return on equity of -37.97% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-22.58%	-362.45%	-6.76%
Zymeworks	-126.92%	-37.97%	-25.31%

PTC Therapeutics has higher revenue and earnings than Zymeworks. PTC Therapeutics is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	4.05	$682.64M	-$2.33	N/A
Zymeworks	$105.96M	16.64	-$81.13M	-$1.37	N/A

PTC Therapeutics currently has a consensus price target of $91.36, indicating a potential upside of 8.20%. Zymeworks has a consensus price target of $36.67, indicating a potential upside of 51.83%. Given Zymeworks' stronger consensus rating and higher probable upside, analysts plainly believe Zymeworks is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.71
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

92.9% of Zymeworks shares are held by institutional investors. 5.5% of PTC Therapeutics shares are held by insiders. Comparatively, 33.5% of Zymeworks shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, PTC Therapeutics had 17 more articles in the media than Zymeworks. MarketBeat recorded 19 mentions for PTC Therapeutics and 2 mentions for Zymeworks. Zymeworks' average media sentiment score of 0.94 beat PTC Therapeutics' score of 0.48 indicating that Zymeworks is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	9 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zymeworks	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Zymeworks beats PTC Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Zymeworks compare to Mirum Pharmaceuticals?

Zymeworks (NASDAQ:ZYME) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

Zymeworks presently has a consensus price target of $36.67, suggesting a potential upside of 51.83%. Mirum Pharmaceuticals has a consensus price target of $139.80, suggesting a potential upside of 13.12%. Given Zymeworks' higher probable upside, equities analysts clearly believe Zymeworks is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Zymeworks has a net margin of -126.92% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-126.92%	-37.97%	-25.31%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

In the previous week, Mirum Pharmaceuticals had 2 more articles in the media than Zymeworks. MarketBeat recorded 4 mentions for Mirum Pharmaceuticals and 2 mentions for Zymeworks. Mirum Pharmaceuticals' average media sentiment score of 0.98 beat Zymeworks' score of 0.94 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zymeworks	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

92.9% of Zymeworks shares are owned by institutional investors. 33.5% of Zymeworks shares are owned by company insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Mirum Pharmaceuticals has higher revenue and earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$105.96M	16.64	-$81.13M	-$1.37	N/A
Mirum Pharmaceuticals	$521.31M	14.46	-$23.36M	-$13.61	N/A

Zymeworks has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market.

Summary

Mirum Pharmaceuticals beats Zymeworks on 8 of the 15 factors compared between the two stocks.

How does Zymeworks compare to Centessa Pharmaceuticals?

Centessa Pharmaceuticals (NASDAQ:CNTA) and Zymeworks (NASDAQ:ZYME) are both pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

Centessa Pharmaceuticals has a net margin of 0.00% compared to Zymeworks' net margin of -126.92%. Zymeworks' return on equity of -37.97% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
Zymeworks	-126.92%	-37.97%	-25.31%

In the previous week, Centessa Pharmaceuticals had 2 more articles in the media than Zymeworks. MarketBeat recorded 4 mentions for Centessa Pharmaceuticals and 2 mentions for Zymeworks. Zymeworks' average media sentiment score of 0.94 beat Centessa Pharmaceuticals' score of 0.72 indicating that Zymeworks is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Centessa Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zymeworks	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Centessa Pharmaceuticals presently has a consensus target price of $41.33, indicating a potential upside of 2.06%. Zymeworks has a consensus target price of $36.67, indicating a potential upside of 51.83%. Given Zymeworks' stronger consensus rating and higher probable upside, analysts clearly believe Zymeworks is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Centessa Pharmaceuticals has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market. Comparatively, Zymeworks has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market.

Zymeworks has higher revenue and earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	N/A	N/A	-$197.53M	-$1.79	N/A
Zymeworks	$105.96M	16.64	-$81.13M	-$1.37	N/A

82.0% of Centessa Pharmaceuticals shares are held by institutional investors. Comparatively, 92.9% of Zymeworks shares are held by institutional investors. 4.1% of Centessa Pharmaceuticals shares are held by insiders. Comparatively, 33.5% of Zymeworks shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Zymeworks beats Centessa Pharmaceuticals on 13 of the 15 factors compared between the two stocks.

How does Zymeworks compare to Regencell Bioscience?

Zymeworks (NASDAQ:ZYME) and Regencell Bioscience (NASDAQ:RGC) are both manufacturing companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

92.9% of Zymeworks shares are held by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are held by institutional investors. 33.5% of Zymeworks shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Regencell Bioscience had 13 more articles in the media than Zymeworks. MarketBeat recorded 15 mentions for Regencell Bioscience and 2 mentions for Zymeworks. Zymeworks' average media sentiment score of 0.94 beat Regencell Bioscience's score of 0.08 indicating that Zymeworks is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zymeworks	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Regencell Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	11 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Regencell Bioscience has a net margin of 0.00% compared to Zymeworks' net margin of -126.92%. Regencell Bioscience's return on equity of 0.00% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-126.92%	-37.97%	-25.31%
Regencell Bioscience	N/A	N/A	N/A

Zymeworks presently has a consensus price target of $36.67, indicating a potential upside of 51.83%. Given Zymeworks' stronger consensus rating and higher probable upside, equities research analysts clearly believe Zymeworks is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Zymeworks has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.66, suggesting that its share price is 66% more volatile than the broader market.

Regencell Bioscience has lower revenue, but higher earnings than Zymeworks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$105.96M	16.64	-$81.13M	-$1.37	N/A
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

Summary

Zymeworks beats Regencell Bioscience on 8 of the 14 factors compared between the two stocks.

Get Zymeworks News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZYME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZYME vs. The Competition

Export

Metric	Zymeworks	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$1.76B	$978.93M	$5.05B	$12.18B
Dividend Yield	N/A	4.84%	13.89%	6.24%
P/E Ratio	N/A	1.50	22.01	24.17
Price / Sales	16.64	119.49	152.53	118.47
Price / Cash	N/A	20.06	36.62	55.62
Price / Book	6.73	8.05	13.62	6.36
Net Income	-$81.13M	-$3.78M	$115.37M	$337.99M
7 Day Performance	4.36%	9.87%	0.82%	0.10%
1 Month Performance	-5.22%	-1.10%	-3.43%	-1.28%
1 Year Performance	N/A	52.18%	10.31%	27.68%

Zymeworks Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZYME Zymeworks	3.0865 of 5 stars	$24.15 +1.6%	$36.67 +51.8%	N/A	$1.76B	$105.96M	N/A	460
RYTM Rhythm Pharmaceuticals	2.7297 of 5 stars	$96.79 flat	$133.13 +37.5%	+75.1%	$6.63B	$217.17M	N/A	140	News Coverage Insider Trade High Trading Volume
PTCT PTC Therapeutics	2.3323 of 5 stars	$78.98 flat	$91.36 +15.7%	+69.4%	$6.55B	$1.73B	N/A	1,410	News Coverage Insider Trade
MIRM Mirum Pharmaceuticals	2.2414 of 5 stars	$107.13 flat	$139.80 +30.5%	+141.9%	$6.53B	$521.31M	N/A	140	Analyst Downgrade High Trading Volume
CNTA Centessa Pharmaceuticals	1.6975 of 5 stars	$40.02 flat	$41.33 +3.3%	N/A	$6.19B	$15M	N/A	200	Short Interest Decrease High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZYME) was last updated on 6/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zymeworks (ZYME) Competitors

ZYME vs. RYTM, PTCT, MIRM, CNTA, and RGC

How does Zymeworks compare to Rhythm Pharmaceuticals?

Summary

How does Zymeworks compare to PTC Therapeutics?

Summary

How does Zymeworks compare to Mirum Pharmaceuticals?

Summary

How does Zymeworks compare to Centessa Pharmaceuticals?

Summary

How does Zymeworks compare to Regencell Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYME vs. The Competition

Zymeworks Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zymeworks (ZYME) Competitors

ZYME vs. RYTM, PTCT, MIRM, CNTA, and RGC

How does Zymeworks compare to Rhythm Pharmaceuticals?

Do institutionals and insiders believe in ZYME or RYTM?

Which has more risk & volatility, ZYME or RYTM?

Does the media prefer ZYME or RYTM?

Do analysts prefer ZYME or RYTM?

Is ZYME or RYTM more profitable?

Which has preferable earnings and valuation, ZYME or RYTM?

Summary

How does Zymeworks compare to PTC Therapeutics?

Which has more volatility & risk, PTCT or ZYME?

Is PTCT or ZYME more profitable?

Which has higher earnings and valuation, PTCT or ZYME?

Do analysts rate PTCT or ZYME?

Do insiders & institutionals believe in PTCT or ZYME?

Does the media favor PTCT or ZYME?

Summary

How does Zymeworks compare to Mirum Pharmaceuticals?

Do analysts rate ZYME or MIRM?

Is ZYME or MIRM more profitable?

Does the media favor ZYME or MIRM?

Do institutionals and insiders hold more shares of ZYME or MIRM?

Which has stronger earnings & valuation, ZYME or MIRM?

Which has more volatility and risk, ZYME or MIRM?

Summary

How does Zymeworks compare to Centessa Pharmaceuticals?

Is CNTA or ZYME more profitable?

Does the media prefer CNTA or ZYME?

Do analysts recommend CNTA or ZYME?

Which has more volatility and risk, CNTA or ZYME?

Which has preferable earnings and valuation, CNTA or ZYME?

Do institutionals & insiders believe in CNTA or ZYME?

Summary

How does Zymeworks compare to Regencell Bioscience?

Do institutionals and insiders believe in ZYME or RGC?

Does the media refer more to ZYME or RGC?

Is ZYME or RGC more profitable?

Do analysts prefer ZYME or RGC?

Which has more volatility and risk, ZYME or RGC?

Which has preferable earnings & valuation, ZYME or RGC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYME vs. The Competition

Zymeworks Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools